Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01617395 · ClinicalTrials.gov registry record
Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
A clinical trial, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- 181
- Enrollment target
NCT01617395: Completed study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT01617395 is a clinical trial that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 181 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01617395 has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- 181 participants
- Enrollment target
Study Summary
Background: \- Research shows that both genes and the environment influence a person s risk for getting multiple sclerosis (MS). However, it is not possible to accurately predict who will develop MS. Researchers want to study people with MS and their family members. They have developed a Genetic and Environmental Risk Score for MS. This score combines information from a person's medical history and genes. It also includes environmental factors that may be related to developing MS. This study will test this risk score to see if it can help predict who will develop MS. Objectives: \- To evaluate a score for genetic and environmental risk factors that may help predict whether a person will develop MS. Eligibility: * Individuals at least 18 years of age who have MS. * Individuals between 18 to 50 years of age who are the parent, brother, sister, or child of a person with MS. Design: * People with MS will allow researchers to look at their personal and medical data. These data will have been collected in other MS-related studies. * Relatives of people with MS will fill out a questionnaire and give blood and saliva samples. They will fill out the questionnaire again one year later. * Some relatives will have additional optional testing. These tests will include a physical exam and imaging studies. There may also be other tests. These tests may be repeated every 1 to 5 years for 20 years.
Primary Outcome
For participants in the cross-sectional cohort, which consists of individuals at highest and lowest risk for MS, the primary outcome measure is the presence or absence of lesions on T2-weighted brain MRI that meet the 2010 MRI criteria for dissemination in space.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2012-08-15 |
What the finished NCT01617395 record still lists
NCT01617395 is an observational study that tracks outcomes without assigning an intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01617395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01617395 about?
NCT01617395 is a clinical study titled "Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility". Background: \- Research shows that both genes and the environment influence a person s risk for getting multiple sclerosis (MS). However, it is not possible to accurately predict who will develop MS. Researchers want to study people with MS and their family members. They have developed a Genetic an...
What is the current status of trial NCT01617395?
This trial is currently completed. The enrollment target is 181 participants. The study started on 2012-08-15.
Who is sponsoring clinical trial NCT01617395?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI